Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the month of February 2021, with a specific reporting date of February 4, 2021. The document serves as a transaction notification regarding share allocations for Non-Executive Directors for the service period of October 1, 2020, to December 31, 2020.
Key Financial Metrics
The filing does not provide consolidated financial metrics such as revenue, profit, cash flow, margins, debt, or liquidity. It exclusively details specific equity transactions involving the acquisition of notional shares.
| Instrument | Price | Total Volume (Shares/ADSs) |
|---|---|---|
| Ordinary Shares (GBP) | £13.61 | 4,520.368 |
| American Depositary Shares (USD) | $37.39 | 3,207.196 |
Material Changes
The filing does not report material changes to the company's financial position or operations compared to prior periods. It solely documents the routine allocation of shares to directors as compensation for the Q4 2020 service period.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, risk factors, or contingencies. It is a regulatory disclosure of director share transactions.
Key Facts for Investor Verification
- Transaction Type: All transactions were acquisitions of notional shares under share allocation arrangements for Non-Executive Directors.
- Service Period: The allocations cover the period from October 1, 2020, to December 31, 2020.
- Transaction Date: All listed transactions were executed on February 3, 2021.
- Participants: The filing lists transactions for Sir Jonathan Symonds, Mr Charles Bancroft, Mr Vindi Banga, Dr Vivienne Cox, Ms Lynn Elsenhans, Dr Laurie Glimcher, Dr Jesse Goodman, Ms Judy Lewent, and Mr Urs Rohner.
- Instrument Split: Transactions were split between Ordinary Shares (denominated in GBP) and American Depositary Shares (denominated in USD).